FGF3 and cholangiocarcinoma: QED Tx pharmaceuticals have developed Infigratinib, a pan-FGFR (1–3) TKI (tyrosine kinase inhibitor), more selective of FGF3 than other FGFRs, which has already shown meaningful clinical activity in cholangiocarcinoma patients.